SOURCE: International Stem Cell Corporation

International Stem Cell Corporation

August 06, 2015 08:30 ET

International Stem Cell Corporation Completes Clinical Testing of a New Compound

CARLSBAD, CA--(Marketwired - August 06, 2015) - International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the Company completed clinical testing of a recently discovered compound, which the Company intends to utilize in skin care products marketed by Company's wholly-owned subsidiary Lifeline Skin Care, Inc. (Lifeline). Topical treatment with the compound showed significant (p<0.01) improvement in skin elasticity and decrease in skin roughness in all subjects 4 and 8 weeks after the start of the study. In addition, the compound-treated group outperformed not only the baseline, but also the Retinol treated group. There were no adverse events reported in the compound-treated group, such as skin irritation, which has been reported as a common side effect of Retinol treatment.

Prior to the clinical study, the compound was tested on different in vitro models: normal human keratinocytes, fibroblasts and 3D model of human skin. In all these models, the recently discovered compound induced up to twice the production of elastin and collagen compared to Retinoic Acid (the active form of Retinol) with none of its toxic characteristics.

The launch of the compound-based products is expected in Q4 2015. Currently Lifeline markets its stem cell-based skin care in the US and Asia via professional and on-line retail channels (www.lifelineskincare.com). The Company believes that these new compound-based products will not only allow it to increase sales and profit margins in its existing markets, but also will allow it to enter the European "high-tech" skin care market.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com and companyblog.intlstemcell.com.

To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

Forward-looking Statements
Statements pertaining to anticipated developments, the expected timing and results of preclinical studies and subsequent regulatory filings, the potential benefits of research programs and products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "intends, " "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, ability to penetrate intended markets, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contact Information